drugset / Trial / NCT06746519
BN104 in Combination With Chemotherapy or Targeted Agents for Acute Myeloid Leukemia
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The Phase I/II trial is to learn the safety, pharmacokinetics, and preliminary efficacy of BN104 taken twice daily combined with Intensive Chemotherapy or Venetoclax/Azacitidine in patients with acute myeloblastic leukemia.
Timeline
- Start
- 2024-12-25
- Primary completion
- 2025-12-30
- Completion
- 2027-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BN104 | Small molecule | 200 mg | Oral |
| Background | Azacitidine | Other / unclassified | 75 mg/m2 | Subcutaneous |
| Background | Cytarabine | Small molecule | 1000 mg/m2 | Intravenous |
| Background | Cytarabine | Small molecule | 2000 mg/m2 | Intravenous |
| Background | Daunorubicin | Small molecule | — | — |
| Background | Idarubicin | Small molecule | — | — |
| Background | Venetoclax | Small molecule | 400 mg | Oral |